Navigation Links
Molecular Genetics Core Facility at Children's Hospital Boston Selects HybSelect from febit for Targeted Resequencing
Date:1/20/2010

LEXINGTON, Mass., and HEIDELBERG, Germany, Jan. 20 /PRNewswire/ -- The Molecular Genetics Core Facility (MGCF) at Children's Hospital Boston chose febit's HybSelect technology which will enable genetics researchers to conduct the highly economic targeted enrichment of genes of interest for resequencing. In January the core facility will be receiving the Geniom RT Analyzer® from febit to perform HybSelect.

"We feel that febit's HybSelect technology will be a powerful tool for our researchers, in conjunction with our Applied Biosystems SOLiD platform, at a reasonable cost," said Hal Schneider, Core Manager of the MGCF. "The ease and flexibility of HybSelect allows us to study a variety of genetic diseases and multiplex bar-coded libraries, making sequence capture projects much more accessible and affordable for our investigators."

The economy of HybSelect increases the potential for widespread use of next generation sequencing in clinical studies. Instead of sequencing the complete genomes of only a few patients, HybSelect enables the analysis of specific genes of interest from large patient cohorts for the same price and data management effort.  The larger patient pool now provides the statistically relevant data that are necessary for clinical studies.

Peer Staehler, CSO at febit, said: "Targeted enrichment and multiplexing are necessary to truly benefit from the advantages of high performance sequencers, and febit has developed HybSelect to meet this need. Together with Life Technologies' SOLiD 3, HybSelect can sequence 16 parallel samples in one run. febit is currently working on an upgrade to a 96-plex barcode set. This will enable sequencing of 2,304 samples in six working days."

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.

The key applications are HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing, and hands-off, amplification free microRNA profiling. Both are taking advantage of the advanced microfluidics of the patented Geniom Biochip to offer the highest degree of automation, flexibility and efficiency available.

For more information, please visit www.febit.com.

About MGCF at Children's Hospital Boston

The Molecular Genetics Core Facility is a non-profit core laboratory in the Program in Genomics and Genetics Division of Children's Hospital Boston offering genomics services for academic research institutions.  The overall objective of the MGCF is to provide a location where researchers can have access to high quality, low cost genomic technology services and expertise in a timely, affordable manner.

For more information please visit http://core.iddrc.org/molecular-genetics

Contact: febit group, Eva Sterzel, eva.sterzel@febit .de, +49 (0)6221 6510-300

Russo Partners, Martina Schwarzkopf, martina.schwarzkopf@russopartnersllc.com, +1 212 845-4292

SOURCE febit

RELATED LINKS
http://www.febit.com

'/>"/>

SOURCE febit
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
2. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
4. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
5. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
6. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
7. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Center for Molecular Medicine One of the First Midwest Labs to Offer Advanced Test for Patients with Metastatic Breast Cancer
10. Delivering Molecular Imaging Solutions Across Clinical Specialties: Siemens Showcases New Technologies at RSNA 2007
11. Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):